Active Clinical Trials at the Vision Institute

Cornea

A Phase 3, multi-center, randomized, parallel, double masked, placebo-controlled clinical study to assess the safety and efficacy of 0.1%

RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2) is currently recruiting. Study Coordinator: Chad Indermill, indermillc@upmc.edu

Pediatrics

Active pediatric clinical trials that are not recruiting include three on myopia.

Two that are not yet recruiting include one on evaluating sequential vs simultaneous spectacles plus patching for amblyopia in children 3-13 and retinal dystrophies associated with rare disease-causing genetic variants.

Retina

Of the six retina clinical trials, five are currently recruiting:

  1. Patients with AMD, nAMD, wAMD, and CNV may be eligible for ASCENT, a randomized, partially masked, controlled, Phase 3 clinical study to evaluate the efficacy of and safety of RGX-314 gene therapy in participants with nAMD. Study coordinator: Sashan Morris, morriss10@upmc.edu.
  2. Patients with inherited retinal diseases may be eligible for NOPROD, a global registry of inherited retinal diseases. Study coordinator: Natalie Anthony, anthonynl2@upmc.edu
  3. PRODYGY is a clinical trial for people with retinitis pigmentosa, a Phase I/II study assessing the safety and tolerability of a single subretinal administration of SPVN06 gene therapy in subjects with rod-cone dystrophy due to a mutation in the RHO, PDE6A, or PDE68 gene. Study coordinator: Natalie Anthony, anthonynl2@upmc.edu
  4. UNI-RARE is a Universal Rare Gene Study: a registry and natural history study of retinal dystrophies associated with rare disease-causing genetic variants. Patients with IRDs or retinitis pigmentosa may inquire. Study coordinator: Chad Indermill, indermillc@upmc.edu
  5. VISTA is a randomized, controlled, masked, multi-center study evaluating the efficacy, safety, and tolerability of two doses of AGTC-501 compared to an untreated control group in male participants with X-linked retinitis pigmentosa. Study coordinator: Dipanwita Samanta, samantad@upmc.edu

The clinical trial that is not yet recruiting is a Phase 1, open-label, dose-escalation study (ENVISION) to evaluate safety of a single intravitreal injection of RTx-015 in patients with retinitis pigmentosa. Study coordinators: Rhonda Dahlstrom, dahlstromrj@upmc.edu and Sashan Morris, morriss10@upmc.edu

Top